What you need to know about GIVETAXFREE.ORG
What you need to know about GIVETAXFREE.ORG
givetaxfree.org

Safety and anti-tumor activity of BAY 2927088 in patients with HER2-mutant NSCLC [Video]

Categories
Pediatric Cancer

Safety and anti-tumor activity of BAY 2927088 in patients with HER2-mutant NSCLC

Nicolas Girard, MD, PhD, Institut Curie, Paris, France, shares findings from a trial on BAY 2927088, a tyrosine kinase inhibitor, for HER2-mutant NSCLC. Among 34 patients treated, 70% showed objective responses and 15% had stable disease. Median progression-free survival was 8.1 months. BAY 2927088 demonstrated a favorable safety profile, with common adverse events being mild diarrhea and rash. The study supports further development of BAY 2927088 in HER2-mutant NSCLC patients. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

FAQs About GiveTaxFree Answered! PART I
FAQs About GiveTaxFree Answered! PART I
givetaxfree.org